The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Research Funding - MSD (Inst)
Pembrolizumab plus FLOT vs FLOT as neoadjuvant and adjuvant therapy in locally advanced gastric and gastroesophageal junction cancer: Interim analysis of the phase 3 KEYNOTE-585 study.
 
Salah-Eddin Al-Batran
Stock and Other Ownership Interests - Immutep; Institut für Klinische Krebsforschung GmbH
Consulting or Advisory Role - AstraZeneca/Daiichi Sankyo; Bristol-Myers Squibb; Eli Lilly Germany; Merck Sharp & Dohme
Speakers' Bureau - AIO gGmbH; Bristol-Myers Squibb; Lilly; MCI Group
Research Funding - AstraZeneca; Bristol-Myers Squibb; Celgene; Eurozyto; Federal Ministry of Education and Research; German Cancer Aid; German Research Foundation; Immutep; Ipsen; Lilly; MSD Sharp & Dohme; Roche; Sanofi; Vifor Pharma
 
Kohei Shitara
Honoraria - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Janssen; Lilly; Ono Pharmaceutical
Consulting or Advisory Role - ALX Oncology; Amgen; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Daiichi Sankyo; Guardant Health; MSD; Novartis; Ono Pharmaceutical; Takeda; Zymeworks
Research Funding - Amgen (Inst); Astellas Pharma (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); MSD (Inst); Ono Pharmaceutical (Inst); PRA Health Sciences (Inst); Taiho Pharmaceutical (Inst)
 
Gunnar Folprecht
Honoraria - Bristol-Myers Squibb; Falk Foundation; Merck KGaA; Merck Sharp & Dohme; Roche/Genentech; Sanofi/Aventis; SERVIER
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Exact Sciences; Incyte; Merck KGaA; Merck Sharp & Dohme; Pierre Fabre; Roche/Genentech; SERVIER
Research Funding - Merck KGaA
 
Markus H. Moehler
Honoraria - Amgen; Astellas Pharma; AstraZeneca/MedImmune; Bayer Schering Pharma; Bristol-Myers Squibb; Daiichi Sankyo Europe GmbH; Idience; Merck Serono; MSD Oncology; Pierre Fabre; Roche/Genentech; Sanofi; Servier; Transcenta; Triptych Health Partners
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; BeiGene; BMS; Daiichi Sankyo Europe GmbH; Lilly; Merck Serono; MSD; Nordic Group; SERVIER; Taiho Pharmaceutical
Research Funding - Amgen (Inst); AstraZeneca (Inst); Leap Therapeutics (Inst); Merck Serono (Inst); MSD (Inst); Taiho Pharmaceutical (Inst)
Travel, Accommodations, Expenses - Amgen; ASCO; Bayer; BeiGene; ESMO; German Cancer Society; Merck Serono; MSD; Roche; Sanofi Pasteur
 
Eray Goekkurt
Consulting or Advisory Role - Bristol-Myers Squibb; Daiichi Sankyo Europe GmbH; MSD Oncology; Pfizer; Roche Pharma AG
Travel, Accommodations, Expenses - SERVIER
 
Irit Ben-Aharon
Research Funding - MSD (Inst)
 
Sara Lonardi
No Relationships to Disclose
 
Stacey Stein
Consulting or Advisory Role - Abbvie; AstraZeneca; Eisai; Exelixis; Genentech/Roche; IMVAX; Ipsen
Research Funding - Genentech (Inst)
 
Ayala Hubert
No Relationships to Disclose
 
Ian Chau
Honoraria - Bristol-Myers Squibb; Eisai; Lilly; Novartis; Roche/Genentech; SERVIER
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; BioNTech SE; Bristol-Myers Squibb; Daiichi Sankyo/Astra Zeneca; Eisai; GlaxoSmithKline; Lilly; Merck Serono; MSD Oncology; OncXerna Therapeutics; Roche/Genentech; Seagen; SERVIER; Sotio; Taiho Oncology; Turning Point Therapeutics
Research Funding - Janssen-Cilag (Inst); Lilly (Inst)
Travel, Accommodations, Expenses - BMS; SERVIER
 
Moshe Mishaeli
Consulting or Advisory Role - AstraZeneca (I)
Speakers' Bureau - Roche (I)
Research Funding - MSD (Inst); Roche (I)
 
Luis Villanueva
Research Funding - Merck Sharp & Dohme; Merck Sharp & Dohme
Travel, Accommodations, Expenses - Merck Serono; Roche; Tecnofarma
 
Petr Kavan
Research Funding - MSD (Inst)
 
Xiao Fang
Employment - Merck Sharp & Dohme
Stock and Other Ownership Interests - Merck
 
Chie-Schin Shih
Employment - Merck Sharp & Dohme
Stock and Other Ownership Interests - Merck Sharp & Dohme
 
Pooja Bhagia
Employment - MSD
Stock and Other Ownership Interests - MSD
 
Lucjan S. Wyrwicz
Honoraria - BeiGene; BMS; MSD
Consulting or Advisory Role - GlaxoSmithKline; SERVIER
Speakers' Bureau - BMS
Travel, Accommodations, Expenses - SERVIER